Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
YoonHwa An/LinkedIn
Sep 14, 2026, 20:53

YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value

YoonHwa An, Founder and Principal Strategist, External Strategic Red Team at Biopharma Business Intelligence Unit, shared a post on LinkedIn:

“Rusfertide in Polycythemia Vera: From Clinical Benefit to Strategic Value

Rusfertide’s FDA approval creates a new option for controlling erythrocytosis in polycythemia vera. For clinicians, payers and investors, the next question is how that benefit translates into treatment decisions and sustainable value.

BBIU’s latest Strategic Report examines the connections:

  • Clinical evidence: What VERIFY’s response endpoint establishes—and the remaining uncertainty around thrombosis, disease progression and long-term outcomes.
  • Health economics: Why avoided phlebotomies alone are unlikely to offset acquisition costs at the reported list price.
  • Market access: How coverage, treatment burden and emerging competitors could influence adoption.
  • Corporate governance: How Protagonist’s agreement with Takeda shifts commercial exposure, and what investors should examine in royalty economics, executive incentives and capital allocation.

The report connects the clinical findings to the decisions facing biopharma executives, investors and healthcare stakeholders.

Available in BBIU’s Strategic Reports. Access currently requires a free account.”

YoonHwa An

Stay updated with Hemostasis Today.

bleeding disorders Blood Erythrocytosis FDA Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine polycythemia vera PV Rusfertide YoonHwa An
NewsFeed